Life Sciences AISeries EInfraℹPathos AI
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.
Company snapshot
- Stage
- Series E
- Funding
- Series E · $237M · Oct 23, 2026
- Status
- published
- Updated
- Nov 4, 2026
- Views
- Category
- Life Sciences AI
- Website
- pathos.com
What they're building
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials. Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.
Founders
Eric Lefkofsky
Co-founder
Ryan Fukushima
Co-founder
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Agentic loops
- Estimated model demand
- High intensity
NYC footprint
- NYC presence
- NYC company or team supported by public sources. Street address has not been verified.
Funding
Latest funding: Series E · $237M · Oct 23, 2026. Lead investor: Bristol Myers Squibb.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Official October 23, 2026 release confirms closed Series E and says the company is based in New York City. Current about page explicitly identifies its 2022 founders Eric Lefkofsky and Ryan Fukushima; Iker Huerga joined as CEO in 2025 and is not added as founder. NYC presence is company-based city evidence only: no street, borough, neighborhood, or occupied office was verified, and the office record remains unverified. Clinical milestones and probability-of-success language describe company plans/methods rather than demonstrated treatment efficacy. Copy is synthesized from cited first-party messaging; no independent performance validation is implied.
- https://www.pathos.com/ ↗
- https://www.pathos.com/about-us ↗
- https://www.pathos.com/pathos-ai-secures-237-million-in-series-e-financing-to-scale-agentic-ai-drug-development-platform-and-advance-oncology-pipeline ↗
Location unresolved · unverified unverified
Street address not public. Current occupancy not confirmed. Primary current funding announcement supports NYC company presence only. No physical office, street, borough, or neighborhood is established. This record must remain unpinned and must not be presented as a verified occupied office.
Pathos AI closes $237M Series E financing ↗Source checked 2026-11-04 · original source 2026-10-23
Notes
Pathos AI is tagged infra based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹ161viewsRecent Activity
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Life Sciences AIWorkflowℹRecent Activity
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations.
Output Labs develops AI systems for mechanistic reasoning, aiming to model how complex systems work and apply those explanations to scientific problems.
Life Sciences AIWorkflowℹ115viewsRecent Activity